Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is a publicly traded healthcare diagnostics company focused on developing AI-powered, epigenetics-based blood tests for the detection and monitoring of cardiovascular disease. The company became publicly listed in 2022 following its business combination with Mana Capital Acquisition Corp., a blank-check company sponsored by Mana Capital Partners LLC that completed its IPO in 2021. Operating in the molecular diagnostics and precision medicine sector, Cardio Diagnostics has continued to advance its epigenetic biomarker platform as a post-merger public entity. The company filed an 8-K current report with the SEC on August 20, 2026. For comprehensive filing history, deal terms, and real-time SPAC data on CDIO and hundreds of other transactions, sign up for full access at SpacDesk.